Effects of Naltrexone Sustained-Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes. Diabetes Care 2013;36:4022–4029

Priscilla Hollander; Alok K. Gupta; Raymond Plodkowski; Frank Greenway; Harold Bays; Colleen Burns; Preston Klassen; Ken Fujioka; for the COR-Diabetes Study Group

doi:10.2337/dc14-er02

Errata

Effects of Naltrexone Sustained-Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes. Diabetes Care 2013;36:4022–4029

Priscilla Hollander,
Alok K. Gupta,
Raymond Plodkowski,
Frank Greenway,
Harold Bays,
Colleen Burns,
Preston Klassen,
Ken Fujioka,
for the COR-Diabetes Study Group

Diabetes Care 2014 Feb; 37(2): 587-587. https://doi.org/10.2337/dc14-er02

In the print version of the article listed above, the following sentence should have been included in the Acknowledgments section: “The authors acknowledge contributions of Eduardo Dunayevich, MD, Amgen, to the design, implementation, and interpretation of the study.” The online version reflects these changes.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

View Abstract